Product ID: SQMIG35I2102
Global PD-1 And PD-L1 Inhibitors Market Size, Share, Growth Analysis, By Type(PD-1 inhibitors, and PD-L1 inhibitors), By Application(Cancer, Autoimmune Diseases), By End-User(Hospitals, Clinics) - Industry Forecast 2024-2031
Report ID:
SQMIG35I2102 |
Region:
Global |
Published Date: February, 2024
Pages:
157
|
Tables:
89 |
Figures:
76
Global PD-1 And PD-L1 Inhibitors Market Insights
PD-1 And PD-L1 Inhibitors Market size was valued at USD 30.3 billion in 2021 and is poised to grow from USD 35.6 billion in 2022 to USD 129.36 billion by 2030, growing at a CAGR of 17.5% in the forecast period (2023-2030).
PD-1/PD-L1 inhibitors are a class of drugs that have revolutionized cancer treatment in recent years. PD-1 (programmed cell death protein 1) and PD-L1 (programmed cell death ligand 1) are two proteins that play a crucial role in regulating the immune system's response to cancer cells. When cancer cells develop, they often produce PD-L1, which binds to PD-1 on the surface of T cells and inhibits their activity. This is an immune evasion mechanism that allows cancer cells to evade the immune system's attack. PD-1/PD-L1 inhibitors work by blocking the interaction between PD-1 and PD-L1, which allows T cells to recognize and attack cancer cells. By unleashing the immune system's natural ability to fight cancer, PD-1/PD-L1 inhibitors have shown remarkable efficacy in a wide range of cancers, including lung cancer, melanoma, bladder cancer, and more. The first PD-1 inhibitor, pembrolizumab (Keytruda), was approved by the FDA in 2014 for the treatment of advanced melanoma. Since then, several other PD-1/PD-L1 inhibitors have been developed and approved for various cancer types, including nivolumab (Opdivo), atezolizumab (Tecentriq), durvalumab (Imfinzi), and avelumab (Bavencio).
The market has witnessed significant growth in recent years, owing to the increasing prevalence of cancer, rising awareness about immunotherapy, and the growing number of approvals for PD-1/PD-L1 inhibitor drugs by regulatory agencies. In addition, the development of combination therapies, which use PD-1/PD-L1 inhibitors in combination with other drugs, has further propelled the growth of the market. North America currently dominates the global PD-1/PD-L1 inhibitors market, owing to the high prevalence of cancer in the region, favorable reimbursement policies, and the presence of a well-established healthcare infrastructure. However, the market is expected to witness significant growth in Asia-Pacific in the coming years, owing to the growing awareness about immunotherapy and the increasing adoption of PD-1/PD-L1 inhibitors in the region. The key players in the global PD-1/PD-L1 inhibitors market include Bristol-Myers Squibb Company, Merck & Co., Inc., Roche Holding AG, AstraZeneca plc, Pfizer Inc., and Novartis AG, among others. These companies are focusing on developing new PD-1/PD-L1 inhibitor drugs, expanding their geographical presence, and entering into partnerships and collaborations to enhance their market position.
However, the high cost of PD-1/PD-L1 inhibitor drugs and the associated adverse effects may hinder the growth of the market to some extent. Moreover, the emergence of new immunotherapies and the increasing focus on personalized medicine may pose a challenge to the growth of the market.
US PD-1 And PD-L1 Inhibitors Market is poised to grow at a sustainable CAGR for the next forecast year.
Global PD-1 And PD-L1 Inhibitors Market Report Snapshots
Want to customize this report?
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATION
USA (+1) 351-333-4748
